Copaxone and Rash maculo-papular - a phase IV clinical study of FDA data

Summary:

Rash maculo-papular is found among people who take Copaxone, especially for people who are female, 40-49 old, have been taking the drug for 5 - 10 years.

The phase IV clinical study analyzes which people take Copaxone and have Rash maculo-papular. It is created by eHealthMe based on reports of 53,633 people who have side effects when taking Copaxone from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Aug, 17, 2022

53,633 people reported to have side effects when taking Copaxone.
Among them, 9 people (0.02%) have Rash maculo-papular.


What is Copaxone?

Copaxone has active ingredients of glatiramer acetate. It is often used in multiple sclerosis. eHealthMe is studying from 52,184 Copaxone users for its effectiveness, alternative drugs and more.

What is Rash maculo-papular?

Rash maculo-papular (red area on the skin that is covered with small confluent bumps) is found to be associated with 1,840 drugs and 1,381 conditions by eHealthMe.

Number of Copaxone and Rash maculo-papular reports submitted per year:

Could Copaxone cause Rash maculo-papular?

Time on Copaxone when people have Rash maculo-papular *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 100 %
  • 10+ years: 0.0 %

Gender of people who have Rash maculo-papular when taking Copaxone *:

  • female: 75 %
  • male: 25 %

Age of people who have Rash maculo-papular when taking Copaxone *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 16.67 %
  • 30-39: 33.33 %
  • 40-49: 33.33 %
  • 50-59: 0.0 %
  • 60+: 16.67 %

Common drugs people take besides Copaxone *:

  1. Aleve: 2 people, 22.22%
  2. Baclofen: 2 people, 22.22%
  3. Zanaflex: 1 person, 11.11%
  4. Allegra: 1 person, 11.11%
  5. Calcium: 1 person, 11.11%
  6. Claritin: 1 person, 11.11%
  7. Fish Oil: 1 person, 11.11%
  8. Flaxseed Oil: 1 person, 11.11%
  9. Lyrica: 1 person, 11.11%
  10. Zetia: 1 person, 11.11%

Common side effects people have besides Rash maculo-papular *:

  1. Itching: 3 people, 33.33%
  2. Rash Erythematous (redness of the skin): 3 people, 33.33%
  3. Erythema Multiforme (a type of hypersensitivity reaction): 2 people, 22.22%
  4. Oedema Peripheral (superficial swelling): 2 people, 22.22%
  5. Hearing Impaired: 2 people, 22.22%
  6. Rashes (redness): 2 people, 22.22%
  7. Auricular Swelling (swelling in the ear): 2 people, 22.22%
  8. Eyelid Oedema (eyelids are swollen and contain excessive fluid): 2 people, 22.22%
  9. Drug Hypersensitivity: 1 person, 11.11%
  10. Drug Eruption (adverse drug reaction of the skin): 1 person, 11.11%

Common conditions people have *:

  1. Osteoporosis Post-Menopausal (weak bone with possibility to break after stopped menstrual cycles): 1 person, 11.11%

* Approximation only. Some reports may have incomplete information.

Do you take Copaxone and have Rash maculo-papular?

Check whether Rash maculo-papular is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

How severe was Rash maculo-papular and when was it recovered:

Expand to all the drugs that have ingredients of glatiramer acetate:

Alternative drugs to, pros and cons of Copaxone:

Common Copaxone side effects:

Browse all side effects of Copaxone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Rash maculo-papular treatments and more:

COVID vaccines that are related to Rash maculo-papular:

Common drugs associated with Rash maculo-papular:

All the drugs that are associated with Rash maculo-papular:

Common conditions associated with Rash maculo-papular:

All the conditions that are associated with Rash maculo-papular:

How the study uses the data?

The study uses data from the FDA. It is based on glatiramer acetate (the active ingredients of Copaxone) and Copaxone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: